Non Resectable Hepatocellular Carcinoma Hcc clinical trials

Explore recruiting non resectable hepatocellular carcinoma hcc clinical trials.

Recruiting non resectable hepatocellular carcinoma hcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Resectable Hepatocellular Carcinoma Hcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular carcinoma (HCC) : Ta-Len-Tra

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on objective response rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Resectable Hepatocellular Carcinoma Hcc trials by city

Non Resectable Hepatocellular Carcinoma Hcc in Toronto Non Resectable Hepatocellular Carcinoma Hcc in Vancouver Non Resectable Hepatocellular Carcinoma Hcc in Montreal Non Resectable Hepatocellular Carcinoma Hcc in Calgary Non Resectable Hepatocellular Carcinoma Hcc in Edmonton Non Resectable Hepatocellular Carcinoma Hcc in Ottawa Non Resectable Hepatocellular Carcinoma Hcc in Winnipeg Non Resectable Hepatocellular Carcinoma Hcc in Quebec City Non Resectable Hepatocellular Carcinoma Hcc in Hamilton Non Resectable Hepatocellular Carcinoma Hcc in Kitchener Non Resectable Hepatocellular Carcinoma Hcc in London Non Resectable Hepatocellular Carcinoma Hcc in Halifax Non Resectable Hepatocellular Carcinoma Hcc in New York Non Resectable Hepatocellular Carcinoma Hcc in Los Angeles Non Resectable Hepatocellular Carcinoma Hcc in Chicago Non Resectable Hepatocellular Carcinoma Hcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease